Peter Powchik - 01 Oct 2023 Form 4 Insider Report for Vaxxinity, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Oct 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Oct 2023, 21:42:02 UTC
Prior SEC filing: 26 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Rene Paula Molina, attorney-in-fact for Peter Powchik

Key filing fact

Peter Powchik filed Form 4 for Vaxxinity, Inc. on 11 Oct 2023.

Key facts

This page summarizes Peter Powchik's Form 4 filing for Vaxxinity, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Oct 2023, 21:42.

Change

Previous filing in this sequence was filed on 26 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VAXX transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +159,744
Change %
Price: $0.000000
Shares after: 159,744
Date: 02 Oct 2023
Ownership: Direct
Underlying class: Class A common stock
Underlying amount: 159,744
Exercise price: $1.27
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options were granted following the Reporting Person joining the Issuer's leadership team as Executive Vice President, Global Scientific Director, effective October 1, 2023, while remaining a member of the Issuer's board of directors.

Footnote F2

These options vest in 12 equal monthly installments beginning on October 1, 2023.

Footnote F3

These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.